期刊
JOURNAL OF PARKINSONS DISEASE
卷 7, 期 -, 页码 S53-S71出版社
IOS PRESS
DOI: 10.3233/JPD-179005
关键词
Alpha-synuclein; Parkinson's disease; dementia with Lewy bodies; multiple system atrophy; protein aggregation; aggregate propagation; neurodegeneration
资金
- UK Medical Research Council [MC_U105184291]
- EU Joint Programme - Neurodegenerative Disease Research
- UK Medical Research Council
- Alzheimer's Research UK
- Gates International
- Astra Zeneca
- Cambridge Biomedical Centre
- Addenbrooke's Hospital Trust
- National Centre for the Replacement, Refinement and Reduction of Animals in Research
- Medical Research Council [MC_U105184291] Funding Source: researchfish
- Parkinson's UK [G-1102] Funding Source: researchfish
- The Cure Parkinsons Trust [CPT11] Funding Source: researchfish
- MRC [MC_U105184291] Funding Source: UKRI
In 2017, it is two hundred years since James Parkinson provided the first complete clinical description of the disease named after him, fifty years since the introduction of high-dose D,L-DOPA treatment and twenty years since alpha-synuclein aggregation came to the fore. In 1998, multiple system atrophy joined Parkinson's disease and dementia with Lewy bodies as the third major synucleinopathy. Here we review our work, which led to the identification of alpha-synuclein in Lewy bodies, Lewy neurites and Papp-Lantos bodies, as well as what has happened since. Some of the experiments described were carried out in collaboration with ML Schmidt, JQ Trojanowski and VMY Lee.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据